CRISPR-Mediated Cancer Modeling

Dear Colleagues,

The discovery of the CRISPR/Cas System was rewarded with the Nobel Prize in 2020, recipients being researchers Emmanuelle Charpentier and Jennifer Doudna. CRISPR technology has revolutionized many areas of research, including cancer research. The possibility to easily generate loss of function studies by the application of CRISPR has opened new possibilities of research. In addition, gain of function studies can be conducted by homologues repaired after CRISPR breaks. This has allowed research to model common loss or gain of function mutations that occur in cancer. CRISPR technology is now used for genome-wide screening by the application of large libraries as well as temporal gene activation or inhibition. Furthermore, as these technologies are both applied in vitro and in vivo, this has opened new research avenues regarding the complexity of cancer biology.

This Special Issue will focus on cancer research where the application of CRISPR has been applied. We will aim to publish articles in this issue where the authors’ application of technology has provided new insight into cancer biology. This issue should contain studies from in vitro, ex vivo, and in vivo applications in order to provide a full understanding of the possibilities of applying CRISPR technology in cancer research.

Dr. Martin Kristian Thomsen
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.